Adial Pharmaceuticals (ADIL) Receivables - Net (2024 - 2025)
Adial Pharmaceuticals (ADIL) posted Receivables - Net of $41758.0 for Q4 2025, down 25.46% sequentially from $56020.0 in Q4 2024, and down 25.46% YoY from $56020.0 in Q4 2024.
Adial Pharmaceuticals (ADIL) Receivables - Net (2024 - 2025) Analysis & Trends
Adial Pharmaceuticals has reported Receivables - Net for 2 years, with the latest figure at $41758.0 in Q4 2025.
- Quarterly Receivables - Net fell 25.46% year-over-year to $41758.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $41758.0 (down 25.46% YoY) and the FY2025 annual result came in at $41758.0, down 25.46% from the prior year.
- Receivables - Net eased to $41758.0 in Q4 2025 per ADIL's latest filing, from $56020.0 in the prior quarter.
- Over five years, Receivables - Net peaked at $56020.0 in Q4 2024 and troughed at $41758.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 41,758.00 |
| Dec 31, 2025 | 41,758.00 |
| Dec 31, 2024 | 56,020.00 |
| Dec 31, 2024 | 56,020.00 |